# A Study to Evaluate the Bioequivalence of Tocilizumab Following Subcutaneous Administration Via an Autoinjector (AI 1000-G2) Versus a Pre-Filled Syringe in Healthy Volunteers

> **NCT02678988** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 189 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DEVICE:** AI-1000 G2
- **DEVICE:** PFS-NSD
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT02678988
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 189 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02678988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02678988, "A Study to Evaluate the Bioequivalence of Tocilizumab Following Subcutaneous Administration Via an Autoinjector (AI 1000-G2) Versus a Pre-Filled Syringe in Healthy Volunteers". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02678988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*